CSIMarket
 


Poseida Therapeutics Inc   (PSTX)
Other Ticker:  
 

Cumulative Poseida Therapeutics Inc 's Leverage Ratio for Trailing Twelve Months Period

PSTX's Leverage Ratio for Trailing Twelve Months Period and Total Liabilities, Equity growth


Select the Comparisons : Select the Ratio:

PSTX Leverage Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Growth -42.83 % 105.62 % 51.94 % 20.09 % 44.06 %
Y / Y Total Liabilities Growth 16.63 % 9.47 % 14 % 62.25 % 114.72 %
Leverage Ratio for Trailing Twelve Months Period 0.89 0.74 0.81 0.86 0.81
Total Ranking # 1838 # 1703 # 1902 # 2340 # 2147
Seq. Equity Growth -8.6 % -14.13 % -16.01 % -13.28 % 228.74 %
Seq. Total Liabilities Growth 31.59 % -7.18 % -5.34 % 0.87 % 23.51 %


Leverage Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to net new borrowings of 31.59%, Leverage Ratio for Trailing Twelve Months Period improved to 0.89, below Poseida Therapeutics Inc 's average Leverage Ratio for Trailing Twelve Months Period.
Leverage Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Biotechnology & Pharmaceuticals industry 111 other companies have achieved lower Leverage Ratio for Trailing Twelve Months Period than Poseida Therapeutics Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Leverage Ratio?
Who are PSTX's Customers?
Leverage Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 112
Sector # 658
S&P 500 # 2060


Leverage Ratio for Trailing Twelve Months Period Statistics
High Average Low
1.5 0.96 0.51
(Jun 30 2021)   (Sep 30 2021)




Companies with similar average Leverage Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Leverage Ratio for Trailing Twelve Months Period
Applied Genetic Technologies Corporation  2.25 
Adaptimmune Therapeutics Plc  2.17 
Valneva Se  2.11 
Old Ayala Inc   1.93 
Biocardia Inc  1.92 
Zura Bio Limited  1.80 
Rubius Therapeutics Inc   1.68 
Evaxion Biotech A  1.65 
Eiger Biopharmaceuticals Inc   1.65 
Champions Oncology Inc   1.63 
Gilead Sciences Inc   1.63 
Meiragtx Holdings Plc  1.63 
Pluri Inc   1.56 
Codiak Biosciences Inc   1.54 
Curis Inc   1.54 
Sutro Biopharma Inc   1.39 
Adma Biologics Inc   1.36 
Biomx Inc   1.29 
Greenlight Biosciences Holdings Pbc  1.26 
X4 Pharmaceuticals Inc  1.25 
Humacyte Inc   1.24 
Logicbio Therapeutics Inc   1.20 
Orchard Therapeutics Plc  1.06 
Innate Pharma Sa  0.93 
Arcellx Inc   0.89 
Adaptive Biotechnologies Corporation  0.89 
Biogen Inc   0.86 
Omega Therapeutics Inc   0.85 
Avalon Globocare Corp   0.85 
Poseida Therapeutics Inc   0.82 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com